GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Consensus Recommendation of “Hold” by Brokerages

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have received a consensus rating of “Hold” from the fifteen analysts that are presently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $3.8125.

Several research firms recently weighed in on GDRX. TD Cowen lifted their price target on GoodRx from $3.00 to $4.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Citigroup upped their price objective on GoodRx from $3.50 to $4.00 and gave the company a “buy” rating in a report on Thursday, May 14th. Weiss Ratings upgraded GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, July 8th. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $3.50 target price on shares of GoodRx in a report on Friday, May 8th.

GoodRx Price Performance

GoodRx stock opened at $3.14 on Monday. The stock has a market cap of $1.08 billion, a P/E ratio of 52.34, a P/E/G ratio of 1.45 and a beta of 1.60. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 0.78. GoodRx has a twelve month low of $1.77 and a twelve month high of $5.81. The company’s 50-day moving average price is $2.79 and its two-hundred day moving average price is $2.50.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.07. GoodRx had a return on equity of 7.90% and a net margin of 2.61%.The company had revenue of $194.01 million during the quarter, compared to analysts’ expectations of $185.40 million. During the same quarter in the previous year, the company posted $0.09 earnings per share. The business’s revenue was down 4.4% on a year-over-year basis. As a group, analysts expect that GoodRx will post 0.17 EPS for the current year.

Hedge Funds Weigh In On GoodRx

A number of hedge funds have recently bought and sold shares of GDRX. AQR Capital Management LLC boosted its holdings in GoodRx by 124.4% in the 1st quarter. AQR Capital Management LLC now owns 282,320 shares of the company’s stock valued at $1,245,000 after purchasing an additional 156,482 shares during the period. Goldman Sachs Group Inc. grew its position in shares of GoodRx by 7.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 783,378 shares of the company’s stock worth $3,455,000 after purchasing an additional 54,783 shares in the last quarter. Jane Street Group LLC bought a new position in shares of GoodRx during the first quarter worth approximately $370,000. Creative Planning bought a new position in shares of GoodRx during the second quarter worth approximately $93,000. Finally, Cetera Investment Advisers acquired a new stake in shares of GoodRx in the second quarter valued at approximately $50,000. 63.77% of the stock is owned by institutional investors.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.